Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00311519 · ClinicalTrials.gov registry record · Phase 4

A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects

A Phase 4 study of Healthy, sponsored by Halozyme Therapeutics.

Completed
Registry status
Phase 4
Development phase
50
Enrollment target
1
Study location

NCT00311519: Completed Phase 4 study of Healthy, sponsored by Halozyme Therapeutics.

NCT00311519 is a Phase 4 study of Healthy that has completed, run by Halozyme Therapeutics. The registered enrollment target is 50 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00311519, a Phase 4 study of Healthy, has completed, sponsored by Halozyme Therapeutics.

COMPLETED
Registry status
Phase 4
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study to test the effectiveness of a study medication to increase how fast a solution called lactated Ringer's is absorbed when put under the skin subcutaneously. The medication to be studied is an enzyme called hyaluronidase, and is a human recombinant form of the enzyme. The drug company name for this medication is Hylenex. Hylenex was currently an investigational medication at the initiation of the study, but received FDA approval during the study. An investigational medication is a medication or formulation of a medication that is not approved by the United States Food and Drug Administration for use in this country but may be used in studies such as this one.

Conditions Studied

Interventions

  • DRUG Hylenex

Study Locations (1)

California

  • West Coast Clinical Trials - Long Beach

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2005-11
Est. Completion 2006-01
Phase Phase 4
Halozyme Therapeutics

31 total trials

What the finished NCT00311519 record still lists

NCT00311519 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Hylenex is the first listed.

NCT00311519 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00311519 about?

NCT00311519 is a clinical study titled "A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects". The purpose of this research study to test the effectiveness of a study medication to increase how fast a solution called lactated Ringer's is absorbed when put under the skin subcutaneously. The medication to be studied is an enzyme called hyaluronidase, and is a human recombinant form of the enzym...

What is the current status of trial NCT00311519?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2005-11. Estimated completion is 2006-01.

What conditions does trial NCT00311519 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00311519?

The interventions under investigation include: Hylenex (DRUG).

Who is sponsoring clinical trial NCT00311519?

This trial is sponsored by Halozyme Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00311519 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00311519's enrollment target sits among peer trials

50 448th of 1090 higher than 618 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

  • NCT01746836 · 50 participants · Phase 2

    Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00311519, the US trial registry maintained by the National Library of Medicine. NCT00311519 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.